(Q47864240)

6 February 2018

title

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children (English)

1 reference

6 February 2018

1 reference

1 reference

Koichi Kamei

1

1 reference

6 February 2018

Shuichi Ito

2

1 reference

6 February 2018

Kandai Nozu

3

1 reference

6 February 2018

Shuichiro Fujinaga

4

1 reference

6 February 2018

Makiko Nakayama

5

1 reference

6 February 2018

Mayumi Sako

6

1 reference

6 February 2018

Mari Saito

7

1 reference

6 February 2018

Maki Yoneko

8

1 reference

6 February 2018

Kazumoto Iijima

9

1 reference

6 February 2018

publication date

7 May 2009

1 reference

6 February 2018

published in

Pediatric Nephrology

1 reference

6 February 2018

volume

24

1 reference

6 February 2018

issue

7

1 reference

6 February 2018

page(s)

1321-1328

1 reference

6 February 2018

https://scigraph.springernature.com/pub.10.1007/s00467-009-1191-0

exact match

0 references

cites work

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

1 reference

12 December 2020

Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

1 reference

12 December 2020

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

12 December 2020

Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?

1 reference

12 December 2020

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

1 reference

12 December 2020

Pharmacokinetic Behavior of Rituximab

1 reference

12 December 2020

Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome

1 reference

12 December 2020

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

1 reference

12 December 2020

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

1 reference

12 December 2020

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

1 reference

12 December 2020

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

1 reference

12 December 2020

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response

1 reference

12 December 2020

Rituximab for refractory focal segmental glomerulosclerosis

1 reference

12 December 2020

Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome

1 reference

12 December 2020

Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

1 reference

12 December 2020

Rituximab in patients with the steroid-resistant nephrotic syndrome

1 reference

12 December 2020

Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years

1 reference

12 December 2020

Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab

1 reference

12 December 2020

Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome

1 reference

12 December 2020

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

1 reference

12 December 2020

Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations

1 reference

12 December 2020

10.1007/S00467-009-1191-0

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018